Advertisement

Ads Placeholder
Loading...

IRIDEX Corporation

IRIXNASDAQ
Healthcare
Medical - Devices
$0.98
$0.03(3.23%)
U.S. Market opens in 65h 26m

IRIDEX Corporation Fundamental Analysis

IRIDEX Corporation (IRIX) shows weak financial fundamentals with a PE ratio of -3.80, profit margin of -8.42%, and ROE of -1.07%. The company generates $0.1B in annual revenue with weak year-over-year growth of -6.17%.

Key Strengths

Cash Position35.78%
PEG Ratio-0.28
Current Ratio1.91

Areas of Concern

ROE-1.07%
Operating Margin-4.88%
We analyze IRIX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -100.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-100.0/100

We analyze IRIX's fundamental strength across five key dimensions:

Efficiency Score

Weak

IRIX struggles to generate sufficient returns from assets.

ROA > 10%
-15.22%

Valuation Score

Excellent

IRIX trades at attractive valuation levels.

PE < 25
-3.80
PEG Ratio < 2
-0.28

Growth Score

Weak

IRIX faces weak or negative growth trends.

Revenue Growth > 5%
-6.17%
EPS Growth > 10%
8.47%

Financial Health Score

Excellent

IRIX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.92
Current Ratio > 1
1.91

Profitability Score

Weak

IRIX struggles to sustain strong margins.

ROE > 15%
-107.47%
Net Margin ≥ 15%
-8.42%
Positive Free Cash Flow
No

Key Financial Metrics

Is IRIX Expensive or Cheap?

P/E Ratio

IRIX trades at -3.80 times earnings. This suggests potential undervaluation.

-3.80

PEG Ratio

When adjusting for growth, IRIX's PEG of -0.28 indicates potential undervaluation.

-0.28

Price to Book

The market values IRIDEX Corporation at 3.42 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.42

EV/EBITDA

Enterprise value stands at -17.92 times EBITDA. This is generally considered low.

-17.92

How Well Does IRIX Make Money?

Net Profit Margin

For every $100 in sales, IRIDEX Corporation keeps $-8.42 as profit after all expenses.

-8.42%

Operating Margin

Core operations generate -4.88 in profit for every $100 in revenue, before interest and taxes.

-4.88%

ROE

Management delivers $-1.07 in profit for every $100 of shareholder equity.

-1.07%

ROA

IRIDEX Corporation generates $-15.22 in profit for every $100 in assets, demonstrating efficient asset deployment.

-15.22%

Following the Money - Real Cash Generation

Operating Cash Flow

IRIDEX Corporation generates limited operating cash flow of $-3.94M, signaling weaker underlying cash strength.

$-3.94M

Free Cash Flow

IRIDEX Corporation generates weak or negative free cash flow of $-3.99M, restricting financial flexibility.

$-3.99M

FCF Per Share

Each share generates $-0.23 in free cash annually.

$-0.23

FCF Yield

IRIX converts -23.55% of its market value into free cash.

-23.55%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.80

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.28

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.42

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.32

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.92

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.91

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.07

vs 25 benchmark

ROA

Return on assets percentage

-0.15

vs 25 benchmark

ROCE

Return on capital employed

-0.16

vs 25 benchmark

How IRIX Stacks Against Its Sector Peers

MetricIRIX ValueSector AveragePerformance
P/E Ratio-3.8028.54 Better (Cheaper)
ROE-107.47%738.00% Weak
Net Margin-8.42%-43982.00% (disorted) Weak
Debt/Equity0.920.34 Weak (High Leverage)
Current Ratio1.912806.01 Neutral
ROA-15.22%-14624.00% (disorted) Weak

IRIX outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews IRIDEX Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-6.60%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

15.70%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

23.24%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ